The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...

Paul Offit knows vaccines. A trained doctor, he spent 26 years working in pediatric infectious disease and studying the ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.

Through Friday, Capital One’s COF stock had returned 10.9% for 2025, while Discover shares had returned 16% as investors became more confident the deal would be completed. The KBW Bank Index had ...